This review provides an overview of the clinical relevance of chemosensitization, giving special reference to the phenolic phytochemicals, curcumin, genistein, epigallocatechin gallate, quercetin, emodin, and resveratrol, which are potential candidates due to their ability to regulate multiple survival pathways without inducing toxicity. We also give a brief summary of all the clinical trials related to the important phytochemicals that emerge as chemosensitizers. The mode of action of these phytochemicals in regulating the key players of the death receptor pathway and multidrug resistance proteins is also abridged. Rigorous efforts in identifying novel chemosensitizers and unraveling their molecular mechanism have resulted in some of the promising candidates such as curcumin, genistein, and polyphenon E, which have gone into clinical trials. Even though considerable research has been conducted in identifying the salient molecular players either contributing to drug efflux or inhibiting DNA repair and apoptosis, both of which ultimately lead to the development of chemoresistance, the interdependence of the molecular pathways leading to chemoresistance is still the impeding factor in the success of chemotherapy. Even though clinical trials are going on to evaluate the chemosensitizing efficacy of phytochemicals such as curcumin, genistein, and polyphenon E, recent results indicate that more intense study is required to confirm their clinical efficacy. Current reports also warrant intense investigation about the use of more phytochemicals such as quercetin, emodin, and resveratrol as chemosensitizers, as all of them have been shown to modulate one or more of the key regulators of chemoresistance. Antioxid. Redox Signal. 18, 1307–1348.
AdhikariS, ChoudhuryS, MitraPS, DubashJJ, SajankilaSP, RoyR. Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem, 8:351–357. 2008.
2.
AggarwalBB, ShishodiaS, TakadaY, BanerjeeS, NewmanRA, Bueso-RamosCE, PriceJE. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res, 11:7490–7498. 2005.
3.
AhmadKA, ClementMV, HanifIM, PervaizS. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res, 64:1452–1459. 2004.
4.
AjabnoorGM, CrookT, ColeyHM. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis, 3:e260. 2012.
5.
AlmeidaL, Vaz-da-SilvaM, FalcaoA, SoaresE, CostaR, LoureiroAI, Fernandes-LopesC, RochaJF, NunesT, WrightL, Soares-da-SilvaP. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res, 53,Suppl 1:S7–S15. 2009.
6.
AnandP, KunnumakkaraAB, NewmanRA, AggarwalBB. Bioavailability of curcumin: problems and promises. Mol Pharm, 4:807–818. 2007.
7.
AnandP, NairHB, SungB, KunnumakkaraAB, YadavVR, TekmalRR, AggarwalBB. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol, 79:330–338. 2010.
8.
AnuchapreedaS, LeechanachaiP, SmithMM, AmbudkarSV, LimtrakulPN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol, 64:573–582. 2002.
9.
AravindanN, VeeraraghavanJ, MadhusoodhananR, HermanTS, NatarajanM. Curcumin regulates low-linear energy transfer gamma-radiation-induced NFkappaB-dependent telomerase activity in human neuroblastoma cells. Int J Radiat Oncol Biol Phys, 79:1206–1215. 2011.
10.
ArltA, GehrzA, MuerkosterS, VorndammJ, KruseML, FolschUR, SchaferH. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene, 22:3243–3251. 2003.
11.
AvrilMF, AamdalS, GrobJJ, HauschildA, MohrP, BonerandiJJ, WeichenthalM, NeuberK, BieberT, GildeK, Guillem PortaV, FraJ, BonneterreJ, SaiagP, KamanabrouD, PehambergerH, SufliarskyJ, Gonzalez LarribaJL, ScherrerA, MenuY. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol, 22:1118–1125. 2004.
12.
AwasthiN, SchwarzMA, SchwarzRE. Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer. HPB (Oxford), 11:600–605. 2009.
13.
BanerjeeM, SinghP, PandaD. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J, 277:3437–3448. 2010.
14.
BanerjeeS, ZhangY, AliS, BhuiyanM, WangZ, ChiaoPJ, PhilipPA, AbbruzzeseJ, SarkarFH. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res, 65:9064–9072. 2005.
15.
BanerjeeS, ZhangY, WangZ, CheM, ChiaoPJ, AbbruzzeseJL, SarkarFH. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer, 120:906–917. 2007.
16.
BaoL, HaqueA, JacksonK, HazariS, MorozK, JetlyR, DashS. Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol, 178:838–852. 2011.
17.
BavaSV, PuliappadambaVT, DeeptiA, NairA, KarunagaranD, AntoRJ. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem, 280:6301–6308. 2005.
18.
BavaSV, SreekanthCN, ThulasidasanAK, AntoNP, CheriyanVT, PuliyappadambaVT, MenonSG, RavichandranSD, AntoRJ. Akt is upstream and MAPKs are downstream of NF-kappaB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol, 43:331–341. 2010.
19.
Bayet-RobertM, KwiatkowskiF, LeheurteurM, GachonF, PlanchatE, AbrialC, Mouret-ReynierMA, DurandoX, BarthomeufC, CholletP. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther, 9:8–14. 2010.
20.
BettuzziS, BrausiM, RizziF, CastagnettiG, PeracchiaG, CortiA. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res, 66:1234–1240. 2006.
21.
BhardwajA, SethiG, Vadhan-RajS, Bueso-RamosC, TakadaY, GaurU, NairAS, ShishodiaS, AggarwalBB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 109:2293–2302. 2007.
22.
BhartiAC, DonatoN, SinghS, AggarwalBB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood, 101:1053–1062. 2003.
23.
BiancoR, CiardielloF, TortoraG. Chemosensitization by antisense oligonucleotides targeting MDM2. Curr Cancer Drug Targets, 5:51–56. 2005.
24.
BobeG, AlbertPS, SansburyLB, LanzaE, SchatzkinA, ColburnNH, CrossAJ. Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila), 3:764–775. 2010.
25.
BoocockDJ, FaustGE, PatelKR, SchinasAM, BrownVA, DucharmeMP, BoothTD, CrowellJA, PerloffM, GescherAJ, StewardWP, BrennerDE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev, 16:1246–1252. 2007.
26.
BrownAL, LaneJ, HolyoakC, NicolB, MayesAE, DaddT. Health effects of green tea catechins in overweight and obese men: a randomised controlled cross-over trial. Br J Nutr, 106:1880–1889. 2011.
27.
BrownVA, PatelKR, ViskadurakiM, CrowellJA, PerloffM, BoothTD, VasilininG, SenA, SchinasAM, PiccirilliG, BrownK, StewardWP, GescherAJ, BrennerDE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res, 70:9003–9011. 2010.
28.
BruningA, VogelM, MylonasI, FrieseK, BurgesA. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets, 11:799–809. 2011.
29.
CaiJ, NiuX, ChenY, HuQ, ShiG, WuH, WangJ, YiJ. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia, 10:41–51. 2008.
30.
Campos-ArroyoD, Martinez-LazcanoJC, Melendez-ZajglaJ. Probenecid is a chemosensitizer in cancer cell lines. Cancer Chemother Pharmacol, 69:495–504. 2012.
31.
CastinoR, PeracchioC, SaliniA, NicotraG, TrincheriNF, DemozM, ValenteG, IsidoroC. Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop. J Cell Mol Med, 13:1096–1109. 2009.
32.
CerviD, TruongAH, LeeJS, SukhaiN, LiYJ, KokiA, Ben-DavidY. Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib. Oncogene, 23:2305–2314. 2004.
33.
ChakrabortyS, StalinS, DasN, ChoudhuryST, GhoshS, SwarnakarS. The use of nano-quercetin to arrest mitochondrial damage and MMP-9 upregulation during prevention of gastric inflammation induced by ethanol in rat. Biomaterials, 33:2991–3001. 2012.
34.
ChanMM, FongD, SopranoKJ, HolmesWF, HeverlingH. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol, 194:63–70. 2003.
35.
ChangQ, LiuZR, WangDY, KumarM, ChenYB, QinRY. Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol, 10:415–418. 2004.
36.
ChapmanPB, EinhornLH, MeyersML, SaxmanS, DestroAN, PanageasKS, BeggCB, AgarwalaSS, SchuchterLM, ErnstoffMS, HoughtonAN, KirkwoodJM. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol, 17:2745–2751. 1999.
37.
ChenC, ZhouJ, JiC. Quercetin: a potential drug to reverse multidrug resistance. Life Sci, 87:333–338. 2010.
38.
ChenJ, JinS, AbrahamV, HuangX, LiuB, MittenMJ, NimmerP, LinX, SmithM, ShenY, ShoemakerAR, TahirSK, ZhangH, AcklerSL, RosenbergSH, MaeckerH, SampathD, LeversonJD, TseC, ElmoreSW. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther, 10:2340–2349. 2011.
39.
ChenJ, KobayashiM, DarmaninS, QiaoY, GullyC, ZhaoR, YeungSC, LeeMH. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene, 28:2581–2592. 2009.
40.
ChenM, ZouX, LuoH, CaoJ, ZhangX, ZhangB, LiuW. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol Int, 33:1008–1019. 2009.
ChenW, WangX, ZhuangJ, ZhangL, LinY. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis, 28:2114–2121. 2007.
43.
ChengAL, HsuCH, LinJK, HsuMM, HoYF, ShenTS, KoJY, LinJT, LinBR, Ming-ShiangW, YuHS, JeeSH, ChenGS, ChenTM, ChenCA, LaiMK, PuYS, PanMH, WangYJ, TsaiCC, HsiehCY. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res, 21:2895–2900. 2001.
44.
ChidambaramM, ManavalanR, KathiresanK. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci, 14:67–77. 2011.
45.
ChirnomasD, TaniguchiT, de la VegaM, VaidyaAP, VassermanM, HartmanAR, KennedyR, FosterR, MahoneyJ, SeidenMV, D'AndreaAD. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther, 5:952–961. 2006.
46.
ChisholmK, BrayBJ, RosengrenRJ. Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs, 15:889–897. 2004.
47.
ChoanE, SegalR, JonkerD, MaloneS, ReaumeN, EapenL, GallantV. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol, 23:108–113. 2005.
48.
ChowHH, CaiY, AlbertsDS, HakimI, DorrR, ShahiF, CrowellJA, YangCS, HaraY. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev, 10:53–58. 2001.
49.
ChowHH, GarlandLL, HsuCH, ViningDR, ChewWM, MillerJA, PerloffM, CrowellJA, AlbertsDS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila), 3:1168–1175. 2010.
50.
ClarkAS, WestK, StreicherS, DennisPA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther, 1:707–717. 2002.
51.
CohenR, SchwartzB, PeriI, ShimoniE. Improving bioavailability and stability of genistein by complexation with high-amylose corn starch. J Agric Food Chem, 59:7932–7938. 2011.
52.
ColeSP, DeeleyRG. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays, 20:931–940. 1998.
53.
ColinD, GimazaneA, LizardG, IzardJC, SolaryE, LatruffeN, DelmasD. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int J Cancer, 124:2780–2788. 2009.
ConklinKA. Cancer chemotherapy and antioxidants. J Nutr, 134:3201S–3204S. 2004.
56.
CritchfieldJW, WelshCJ, PhangJM, YehGC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol, 48:1437–1445. 1994.
57.
Cruz-CorreaM, ShoskesDA, SanchezP, ZhaoR, HylindLM, WexnerSD, GiardielloFM. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol, 4:1035–1038. 2006.
58.
CumminsJM, KohliM, RagoC, KinzlerKW, VogelsteinB, BunzF. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res, 64:3006–3008. 2004.
59.
DaiQ, ShuXO, JinF, PotterJD, KushiLH, TeasJ, GaoYT, ZhengW. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer, 85:372–378. 2001.
60.
DaltonWS, CrowleyJJ, SalmonSS, GroganTM, LaufmanLR, WeissGR, BonnetJD. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer, 75:815–820. 1995.
61.
DavisTA, MungunsukhO, ZinsS, DayRM, LandauerMR. Genistein induces radioprotection by hematopoietic stem cell quiescence. Int J Radiat Biol, 84:713–726. 2008.
62.
De LaurentiisM, ArpinoG, MassarelliE, RuggieroA, CarlomagnoC, CiardielloF, TortoraG, D'AgostinoD, CaputoF, CancelloG, MontagnaE, MalorniL, ZinnoL, LauriaR, BiancoAR, De PlacidoS. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res, 11:4741–4748. 2005.
63.
DeebD, JiangH, GaoX, Al-HolouS, DanylukAL, DulchavskySA, GautamSC. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1–6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J Pharmacol Exp Ther, 321:616–625. 2007.
64.
DeebD, JiangH, GaoX, HafnerMS, WongH, DivineG, ChapmanRA, DulchavskySA, GautamSC. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther, 3:803–812. 2004.
65.
deGraffenriedLA, ChandrasekarB, FriedrichsWE, DonzisE, SilvaJ, HidalgoM, FreemanJW, WeissGR. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol, 15:885–890. 2004.
66.
DelmasD, RebeC, MicheauO, AthiasA, GambertP, GrazideS, LaurentG, LatruffeN, SolaryE. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 23:8979–8986. 2004.
67.
deVere WhiteRW, HackmanRM, SoaresSE, BeckettLA, LiY, SunB. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology, 63:259–263. 2004.
68.
DhillonN, AggarwalBB, NewmanRA, WolffRA, KunnumakkaraAB, AbbruzzeseJL, NgCS, BadmaevV, KurzrockR. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res, 14:4491–4499. 2008.
69.
DomagkD, Bluthner-HasslerC, KuglerA, KallerhoffM, RingertRH. Influence of vinblastine on DNA parameters and multidrug resistance in renal cell carcinoma in vitro. Urol Res, 26:123–127. 1998.
70.
DoyleLA, YangW, AbruzzoLV, KrogmannT, GaoY, RishiAK, RossDD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 95:15665–15670. 1998.
71.
DuB, JiangL, XiaQ, ZhongL. Synergistic inhibitory effects of curcumin and 5-fluorouracil on the growth of the human colon cancer cell line HT-29. Chemotherapy, 52:23–28. 2006.
72.
DuG, LinH, WangM, ZhangS, WuX, LuL, JiL, YuL. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells. Cancer Chemother Pharmacol, 65:277–287. 2010.
73.
DuG, LinH, YangY, ZhangS, WuX, WangM, JiL, LuL, YuL, HanG. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol, 10:819–826. 2010.
74.
DuM, YangX, HartmanJA, CookePS, DoergeDR, JuYH, HelferichWG. Low-dose dietary genistein negates the therapeutic effect of tamoxifen in athymic nude mice. Carcinogenesis, 33:895–901. 2012.
75.
El-DeiryWS. The role of p53 in chemosensitivity and radiosensitivity. Oncogene, 22:7486–7495. 2003.
76.
El-RayesBF, AliS, AliIF, PhilipPA, AbbruzzeseJ, SarkarFH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res, 66:10553–10559. 2006.
77.
El-RayesBF, PhilipPA, SarkarFH, ShieldsAF, FerrisAM, HessK, KasebAO, JavleMM, VaradhacharyGR, WolffRA, AbbruzzeseJL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs, 29:694–699. 2011.
EpelbaumR, SchafferM, VizelB, BadmaevV, Bar-SelaG. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer, 62:1137–1141. 2010.
80.
ErmakovaSP, KangBS, ChoiBY, ChoiHS, SchusterTF, MaWY, BodeAM, DongZ. (−)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res, 66:9260–9269. 2006.
81.
FarabegoliF, PapiA, BartoliniG, OstanR, OrlandiM. (−)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine, 17:356–362. 2010.
82.
FedericoA, MorgilloF, TuccilloC, CiardielloF, LoguercioC. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer, 121:2381–2386. 2007.
83.
FerryDR, SmithA, MalkhandiJ, FyfeDW, deTakatsPG, AndersonD, BakerJ, KerrDJ. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res, 2:659–668. 1996.
84.
FramptonGA, LazcanoEA, LiH, MohamadA, DeMorrowS. Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. Lab Invest, 90:1325–1338. 2010.
85.
FukuiM, YamabeN, ZhuBT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer, 46:1882–1891. 2010.
86.
FuldaS, DebatinKM. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer, 41:786–798. 2005.
87.
FuldaS, DebatinKM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene, 23:6702–6711. 2004.
88.
FuldaS, MeyerE, DebatinKM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 21:2283–2294. 2002.
89.
GandapuU, ChaitanyaRK, KishoreG, ReddyRC, KondapiAK. Curcumin-loaded apotransferrin nanoparticles provide efficient cellular uptake and effectively inhibit HIV-1 replication in vitro. PLoS One, 6:e23388. 2011.
90.
GandhiL, CamidgeDR, Ribeiro de OliveiraM, BonomiP, GandaraD, KhairaD, HannCL, McKeeganEM, LitvinovichE, HemkenPM, DiveC, EnschedeSH, NolanC, ChiuYL, BusmanT, XiongH, KrivoshikAP, HumerickhouseR, ShapiroGI, RudinCM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol, 29:909–916. 2011.
91.
GarceaG, BerryDP, JonesDJ, SinghR, DennisonAR, FarmerPB, SharmaRA, StewardWP, GescherAJ. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev, 14:120–125. 2005.
92.
GargAK, HortobagyiGN, AggarwalBB, SahinAA, BuchholzTA. Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol, 15:405–411. 2003.
93.
GerlR, VauxDL. Apoptosis in the development and treatment of cancer. Carcinogenesis, 26:263–270. 2005.
94.
GhiringhelliF, RebeC, HichamiA, DelmasD. Immunomodulation and anti-inflammatory roles of polyphenols as anticancer agents. Anticancer Agents Med Chem, 12:852–873. 2012.
95.
GuoQ, ChenY, ZhangB, KangM, XieQ, WuY. Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition. Biochem Pharmacol, 77:1674–1683. 2009.
96.
GuoX, MaN, WangJ, SongJ, BuX, ChengY, SunK, XiongH, JiangG, ZhangB, WuM, WeiL. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer, 8:375. 2008.
97.
GuoXL, LiD, HuF, SongJR, ZhangSS, DengWJ, SunK, ZhaoQD, XieXQ, SongYJ, WuMC, WeiLX. Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett, 320:171–179. 2012.
98.
GuptaSC, KannappanR, ReuterS, KimJH, AggarwalBB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci, 1215:150–160. 2011.
99.
HarariD, YardenY. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene, 19:6102–6114. 2000.
HarikumarKB, KunnumakkaraAB, SethiG, DiagaradjaneP, AnandP, PandeyMK, GelovaniJ, KrishnanS, GuhaS, AggarwalBB. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer, 127:257–268. 2010.
102.
HeZY, ShiCB, WenH, LiFL, WangBL, WangJ. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest, 29:208–213. 2011.
103.
HenningSM, AronsonW, NiuY, CondeF, LeeNH, SeeramNP, LeeRP, LuJ, HarrisDM, MoroA, HongJ, Pak-ShanL, BarnardRJ, ZiaeeHG, CsathyG, GoVL, WangH, HeberD. Tea polyphenols and theaflavins are present in prostate tissue of humans and mice after green and black tea consumption. J Nutr, 136:1839–1843. 2006.
104.
HorvathZ, SaikoP, IllmerC, MadlenerS, HoechtlT, BauerW, ErkerT, JaegerW, Fritzer-SzekeresM, SzekeresT. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol, 33:329–335. 2005.
105.
HourTC, ChenJ, HuangCY, GuanJY, LuSH, PuYS. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate, 51:211–218. 2002.
106.
HowellsLM, BerryDP, ElliottPJ, JacobsonEW, HoffmannE, HegartyB, BrownK, StewardWP, GescherAJ. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila), 4:1419–1425. 2011.
107.
HsiehDS, WangH, TanSW, HuangYH, TsaiCY, YehMK, WuCJ. The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials, 32:7633–7640. 2011.
108.
HuangQ, YuH, RuQ. Bioavailability and delivery of nutraceuticals using nanotechnology. J Food Sci, 75:R50–R57. 2010.
109.
HuangXZ, WangJ, HuangC, ChenYY, ShiGY, HuQS, YiJ. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther, 7:468–475. 2008.
110.
HwangJT, HaJ, ParkIJ, LeeSK, BaikHW, KimYM, ParkOJ. Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett, 247:115–121. 2007.
111.
HwangJT, HaJ, ParkOJ. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun, 332:433–440. 2005.
112.
IgneyFH, KrammerPH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer, 2:277–288. 2002.
113.
IkeguchiM, LiuJ, KaibaraN. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis, 7:23–29. 2002.
114.
IvanovVN, PartridgeMA, JohnsonGE, HuangSX, ZhouH, HeiTK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res, 314:1163–1176. 2008.
115.
JacquemontC, SimonJA, D'AndreaAD, TaniguchiT. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin. Mol Cancer, 11:26. 2012.
116.
Jakubowicz-GilJ, LangnerE, WertelI, PiersiakT, RzeskiW. Temozolomide, quercetin and cell death in the MOGGCCM astrocytoma cell line. Chem Biol Interact, 188:190–203. 2010.
117.
Jakubowicz-GilJ, PaduchR, PiersiakT, GlowniakK, GawronA, Kandefer-SzerszenM. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol, 69:1343–1350. 2005.
118.
JatoiA, EllisonN, BurchPA, SloanJA, DakhilSR, NovotnyP, TanW, FitchTR, RowlandKM, YoungCY, FlynnPJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer, 97:1442–1446. 2003.
JazirehiAR, BonavidaB. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther, 3:71–84. 2004.
121.
JeongJH, AnJY, KwonYT, LiLY, LeeYJ. Quercetin-induced ubiquitination and down-regulation of Her-2/neu. J Cell Biochem, 105:585–595. 2008.
122.
JianL, XieLP, LeeAH, BinnsCW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer, 108:130–135. 2004.
123.
JinCY, ParkC, CheongJ, ChoiBT, LeeTH, LeeJD, LeeWH, KimGY, RyuCH, ChoiYH. Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. Cancer Lett, 257:56–64. 2007.
124.
JinCY, ParkC, KimGY, LeeSJ, KimWJ, ChoiYH. Genistein enhances TRAIL-induced apoptosis through inhibition of p38 MAPK signaling in human hepatocellular carcinoma Hep3B cells. Chem Biol Interact, 180:143–150. 2009.
125.
JinHS, LeeDH, KimDH, ChungJH, LeeSJ, LeeTH. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res, 69:1782–1791. 2009.
126.
JohnsonJJ, NihalM, SiddiquiIA, ScarlettCO, BaileyHH, MukhtarH, AhmadN. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res, 55:1169–1176. 2011.
127.
JungEM, LimJH, LeeTJ, ParkJW, ChoiKS, KwonTK. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5)Carcinogenesis, 26:1905–1913. 2005.
128.
JungYH, HeoJ, LeeYJ, KwonTK, KimYH. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci, 86:351–357. 2010.
129.
KamatAM, TharakanST, SungB, AggarwalBB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res, 69:8958–8966. 2009.
130.
KaminskiBM, SteinhilberD, SteinJM, UlrichS. Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol, 13:137–146. 2012.
131.
KanaiM, YoshimuraK, AsadaM, ImaizumiA, SuzukiC, MatsumotoS, NishimuraT, MoriY, MasuiT, KawaguchiY, YanagiharaK, YazumiS, ChibaT, GuhaS, AggarwalBB. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol, 68:157–164. 2011.
132.
KaneRC, FarrellAT, SridharaR, PazdurR. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res, 12:2955–2960. 2006.
133.
KarnakD, XuL. Chemosensitization of prostate cancer by modulating Bcl-2 family proteins. Curr Drug Targets, 11:699–707. 2010.
134.
KarunagaranD, TzaharE, BeerliRR, ChenX, Graus-PortaD, RatzkinBJ, SegerR, HynesNE, YardenY. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J, 15:254–264. 1996.
135.
KatsmanA, UmezawaK, BonavidaB. Chemosensitization and immunosensitization of resistant cancer cells to apoptosis and inhibition of metastasis by the specific NF-kappaB inhibitor DHMEQ. Curr Pharm Des, 15:792–808. 2009.
136.
KhanSA, ChattertonRT, MichelN, BrykM, LeeO, IvancicD, HeinzR, ZallesCM, HelenowskiIB, JovanovicBD, FrankeAA, BoslandMC, WangJ, HansenNM, BethkeKP, DewA, CoomesM, BerganRC. Soy isoflavone supplementation for breast cancer risk reduction: a randomized phase II trial. Cancer Prev Res (Phila), 5:309–319. 2012.
137.
KimJW, AminAR, ShinDM. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev Res (Phila), 3:900–909. 2010.
138.
KimJY, KimEH, ParkSS, LimJH, KwonTK, ChoiKS. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation. J Cell Biochem, 105:1386–1398. 2008.
139.
KimTH, JiangHH, YounYS, ParkCW, TakKK, LeeS, KimH, JonS, ChenX, LeeKC. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm, 403:285–291. 2011.
140.
KimYH, LeeDH, JeongJH, GuoZS, LeeYJ. Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochem Pharmacol, 75:1946–1958. 2008.
141.
KimYH, LeeYJ. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. J Cell Biochem, 100:998–1009. 2007.
142.
KitazonoM, SumizawaT, TakebayashiY, ChenZS, FurukawaT, NagayamaS, TaniA, TakaoS, AikouT, AkiyamaS. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst, 91:1647–1653. 1999.
143.
KnuefermannC, LuY, LiuB, JinW, LiangK, WuL, SchmidtM, MillsGB, MendelsohnJ, FanZ. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene, 22:3205–3212. 2003.
144.
KoJC, SuYJ, LinST, JhanJY, CiouSC, ChengCM, ChiuYF, KuoYH, TsaiMS, LinYW. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer, 69:155–164. 2010.
145.
KohnoK, UchiumiT, NiinaI, WakasugiT, IgarashiT, MomiiY, YoshidaT, MatsuoK, MiyamotoN, IzumiH. Transcription factors and drug resistance. Eur J Cancer, 41:2577–2586. 2005.
146.
KoongAC, ChenEY, GiacciaAJ. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res, 54:1425–1430. 1994.
147.
KudoC, YamakoshiH, SatoA, OhoriH, IshiokaC, IwabuchiY, ShibataH. Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma. Anticancer Res, 31:3719–3726. 2011.
148.
KuharM, ImranS, SinghN. Curcumin and quercetin combined with cisplatin to induce apoptosis in human laryngeal carcinoma Hep-2 cells through the mitochondrial pathway. J Cancer Mol, 3:121–128. 2007.
149.
KunnumakkaraAB, DiagaradjaneP, AnandP, HarikumarKB, DeorukhkarA, GelovaniJ, GuhaS, KrishnanS, AggarwalBB. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer, 125:2187–2197. 2009.
150.
KunnumakkaraAB, GuhaS, KrishnanS, DiagaradjaneP, GelovaniJ, AggarwalBB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res, 67:3853–3861. 2007.
151.
KunosCA, SillMW, BuekersTE, WalkerJL, SchilderJM, YamadaSD, WaggonerSE, MohiuddinM, FracassoPM. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol, 120:224–228. 2011.
152.
KurahashiN, SasazukiS, IwasakiM, InoueM, TsuganeS. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol, 167:71–77. 2008.
153.
KurokawaT, HeG, SiddikZH. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner. Cancer Chemother Pharmacol, 65:427–436. 2010.
154.
KwanW, DuncanG, Van PattenC, LiuM, LimJ. A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr Cancer, 62:198–207. 2010.
155.
KweonMH, AdhamiVM, LeeJS, MukhtarH. Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. J Biol Chem, 281:33761–33772. 2006.
156.
KweonSH, SongJH, KimTS. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun, 395:104–110. 2010.
157.
la PorteC, VoducN, ZhangG, SeguinI, TardiffD, SinghalN, CameronDW. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet, 49:449–454. 2010.
158.
LaiGH, ZhangZ, SiricaAE. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther, 2:265–271. 2003.
159.
LambertJD, HongJ, KimDH, MishinVM, YangCS. Piperine enhances the bioavailability of the tea polyphenol (−)-epigallocatechin-3-gallate in mice. J Nutr, 134:1948–1952. 2004.
160.
Landis-PiwowarKR, MilacicV, ChenD, YangH, ZhaoY, ChanTH, YanB, DouQP. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat, 9:263–273. 2006.
161.
LangM, HensonR, BraconiC, PatelT. Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. Liver Int, 29:670–677. 2009.
162.
LanyiA, DebD, SeymourRC, Ludes-MeyersJH, SublerMA, DebS. “Gain of function” phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. Oncogene, 16:3169–3176. 1998.
163.
LauA, VilleneuveNF, SunZ, WongPK, ZhangDD. Dual roles of Nrf2 in cancer. Pharmacol Res, 58:262–270. 2008.
164.
LazarevicB, BoezelijnG, DiepLM, KvernrodK, OgrenO, RambergH, MoenA, WesselN, BergRE, Egge-JacobsenW, HammarstromC, SvindlandA, KucukO, SaatciogluF, TaskenKA, KarlsenSJ. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer, 63:889–898. 2011.
165.
LeeAS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res, 67:3496–3499. 2007.
166.
LeeCK, ParkKK, ChungAS, ChungWY. Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. Food Chem Toxicol, 50:2565–2574. 2012.
167.
LehnertM, MrossK, SchuellerJ, ThuerlimannB, KroegerN, KupperH. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br J Cancer, 77:1155–1163. 1998.
168.
Lev-AriS, StrierL, KazanovD, Madar-ShapiroL, Dvory-SobolH, PinchukI, MarianB, LichtenbergD, ArberN. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res, 11:6738–6744. 2005.
LevDC, RuizM, MillsL, McGaryEC, PriceJE, Bar-EliM. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2:753–763. 2003.
171.
LiF, AmbrosiniG, ChuEY, PlesciaJ, TogninS, MarchisioPC, AltieriDC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature, 396:580–584. 1998.
172.
LiF, SethiG. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta, 1805:167–180. 2010.
173.
LiJ, LiuP, MaoH, WangaA, ZhangX. Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep, 21:1605–1610. 2009.
174.
LiY, AhmedF, AliS, PhilipPA, KucukO, SarkarFH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res, 65:6934–6942. 2005.
175.
LiY, EllisKL, AliS, El-RayesBF, Nedeljkovic-KurepaA, KucukO, PhilipPA, SarkarFH. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas, 28:e90–e95. 2004.
176.
LiY, KucukO, HussainM, AbramsJ, CherML, SarkarFH. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res, 66:4816–4825. 2006.
177.
LiangC, LiH, ShenC, LaiJ, ShiZ, LiuB, TaoHM. Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-kappaB pathway. Anticancer Agents Med Chem, 12:554–563. 2012.
178.
LinC, YuY, ZhaoHG, YangA, YanH, CuiY. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol, 2011, DOI:10.1016/j.radonc.2011.10.023.
179.
LinCJ, LeeCC, ShihYL, LinTY, WangSH, LinYF, ShihCM. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med, 52:377–391. 2012.
180.
LinYG, KunnumakkaraAB, NairA, MerrittWM, HanLY, Armaiz-PenaGN, KamatAA, SpannuthWA, GershensonDM, LutgendorfSK, AggarwalBB, SoodAK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res, 13:3423–3430. 2007.
LiuJD, ChenSH, LinCL, TsaiSH, LiangYC. Inhibition of melanoma growth and metastasis by combination with (−)-epigallocatechin-3-gallate and dacarbazine in mice. J Cell Biochem, 83:631–642. 2001.
183.
LlobetD, EritjaN, EncinasM, LlechaN, YeramianA, PallaresJ, SorollaA, Gonzalez-TalladaFJ, Matias-GuiuX, DolcetX. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene, 27:2513–2524. 2008.
184.
LuoT, WangJ, YinY, HuaH, JingJ, SunX, LiM, ZhangY, JiangY. (−)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res, 12:R8. 2010.
185.
MabuchiS, OhmichiM, KimuraA, HisamotoK, HayakawaJ, NishioY, AdachiK, TakahashiK, Arimoto-IshidaE, NakatsujiY, TasakaK, MurataY. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem, 277:33490–33500. 2002.
186.
MaiZ, BlackburnGL, ZhouJR. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog, 46:534–542. 2007.
187.
ManjuS, SreenivasanK. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci, 368:144–151. 2012.
188.
MaoQQ, BaiY, LinYW, ZhengXY, QinJ, YangK, XieLP. Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res, 54:1574–1584. 2010.
189.
MasudaM, SuzuiM, WeinsteinIB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res, 7:4220–4229. 2001.
190.
McConkeyDJ, ZhuK. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat, 11:164–179. 2008.
191.
McFadyenMC, McLeodHL, JacksonFC, MelvinWT, DoehmerJ, MurrayGI. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol, 62:207–212. 2001.
192.
McLartyJ, BigelowRL, SmithM, ElmajianD, AnkemM, CardelliJA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila), 2:673–682. 2009.
193.
MeiY, WeiD, LiuJ. Reversal of cancer multidrug resistance by tea polyphenol in KB cells. J Chemother, 15:260–265. 2003.
194.
MendelsohnJ, BaselgaJ. The EGF receptor family as targets for cancer therapy. Oncogene, 19:6550–6565. 2000.
195.
MessingE, GeeJR, SaltzsteinDR, KimK, diSant'AgneseA, KolesarJ, HarrisL, FaerberA, HavighurstT, YoungJM, EfrosM, GetzenbergRH, WheelerMA, TangreaJ, ParnesH, HouseM, BusbyJE, HohlR, BaileyH. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila), 5:621–630. 2012.
196.
MickischGH, KossigJ, TschadaRK, KeilhauerG, SchlickE, AlkenPM. Circumvention of multidrug resistance mediated by P-170 glycoprotein using calcium antagonists in primary human renal cell carcinoma. Urol Int, 47:118–125. 1991.
197.
MilacicV, BanerjeeS, Landis-PiwowarKR, SarkarFH, MajumdarAP, DouQP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res, 68:7283–7292. 2008.
198.
MiltykW, CraciunescuCN, FischerL, JeffcoatRA, KochMA, LopaczynskiW, MahoneyC, CrowellJ, PaglieriJ, ZeiselSH. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr, 77:875–882. 2003.
199.
MinnAJ, RudinCM, BoiseLH, ThompsonCB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood, 86:1903–1910. 1995.
200.
MitaAC, MitaMM, NawrockiST, GilesFJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res, 14:5000–5005. 2008.
201.
MittalA, PateMS, WylieRC, TollefsbolTO, KatiyarSK. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int J Oncol, 24:703–710. 2004.
202.
MohammadRM, Al-KatibA, AboukameelA, DoergeDR, SarkarF, KucukO. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther, 2:1361–1368. 2003.
203.
MontiE, GariboldiMB. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol, 4:62–77. 2011.
204.
MorganMJ, LiuZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res, 21:103–115. 2011.
205.
MorishitaN, TsukaharaH, ChayamaK, IshidaT, WashioK, MiyamuraT, YamashitaN, OdaM, MorishimaT. Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer, 59:83–89. 2012.
206.
MorrowDM, FitzsimmonsPE, ChopraM, McGlynnH. Dietary supplementation with the anti-tumour promoter quercetin: its effects on matrix metalloproteinase gene regulation. Mutat Res, 480–481:269–276. 2001.
207.
MosieniakG, AdamowiczM, AlsterO, JaskowiakH, SzczepankiewiczAA, WilczynskiGM, CiechomskaIA, SikoraE. Curcumin induces permanent growth arrest of human colon cancer cells: Link between senescence and autophagy. Mech Ageing Dev, 133:444–455. 2012.
208.
MotylT, GajkowskaB, ZarzynskaJ, GajewskaM, Lamparska-PrzybyszM. Apoptosis and autophagy in mammary gland remodeling and breast cancer chemotherapy. J Physiol Pharmacol, 57,Suppl 7:17–32. 2006.
209.
MulhollandPJ, FerryDR, AndersonD, HussainSA, YoungAM, CookJE, HodgkinE, SeymourLW, KerrDJ. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann Oncol, 12:245–248. 2001.
210.
NairKL, ThulasidasanAK, DeepaG, AntoRJ, KumarGS. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. Int J Pharm, 425:44–52. 2012.
211.
NakamuraY, YogosawaS, IzutaniY, WatanabeH, OtsujiE, SakaiT. A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer, 8:100. 2009.
212.
NambiarD, RajamaniP, SinghRP. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy. Mutat Res, 728:139–157. 2011.
213.
NguyenAV, MartinezM, StamosMJ, MoyerMP, PlanutisK, HopeC, HolcombeRF. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res, 1:25–37. 2009.
214.
NihalM, AhsanH, SiddiquiIA, MukhtarH, AhmadN, WoodGS. (−)-Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle, 8:2057–2063. 2009.
215.
NishidaN, YamashitaS, MimoriK, SudoT, TanakaF, ShibataK, YamamotoH, IshiiH, DokiY, MoriM. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann Surg Oncol, 19:3065–3071. 2012.
216.
NishikawaT, NakajimaT, MoriguchiM, JoM, SekoguchiS, IshiiM, TakashimaH, KatagishiT, KimuraH, MinamiM, ItohY, KagawaK, OkanoueT. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins. J Hepatol, 44:1074–1082. 2006.
NotarbartoloM, PomaP, PerriD, DusonchetL, CervelloM, D'AlessandroN. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett, 224:53–65. 2005.
219.
OhnumaT, MatsumotoT, ItoiA, KawanaA, NishiyamaT, OguraK, HiratsukaA. Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract. Biochem Biophys Res Commun, 413:623–629. 2011.
220.
OrlowskiRZ. Bortezomib in combination with other therapies for the treatment of multiple myeloma. J Natl Compr Canc Netw, 2,Suppl 4:S16–S20. 2004.
221.
ParikhSA, KantarjianH, SchimmerA, WalshW, AsatianiE, El-ShamiK, WintonE, VerstovsekS. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk, 10:285–289. 2010.
222.
ParkSY, SeolDW. Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun, 295:515–518. 2002.
223.
PatelBB, SenguptaR, QaziS, VachhaniH, YuY, RishiAK, MajumdarAP. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer, 122:267–273. 2008.
224.
PatelKR, BrownVA, JonesDJ, BrittonRG, HemingwayD, MillerAS, WestKP, BoothTD, PerloffM, CrowellJA, BrennerDE, StewardWP, GescherAJ, BrownK. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res, 70:7392–7399. 2010.
225.
PendletonJM, TanWW, AnaiS, ChangM, HouW, ShiverickKT, RosserCJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer, 8:132. 2008.
226.
PerezRP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer, 34:1535–1542. 1998.
227.
PervaizS, ClementMV. Tumor intracellular redox status and drug resistance—serendipity or a causal relationship?Curr Pharm Des, 10:1969–1977. 2004.
228.
PingSY, HourTC, LinSR, YuDS. Taxol synergizes with antioxidants in inhibiting hormal refractory prostate cancer cell growth. Urol Oncol, 28:170–179. 2010.
229.
PistersKM, NewmanRA, ColdmanB, ShinDM, KhuriFR, HongWK, GlissonBS, LeeJS. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol, 19:1830–1838. 2001.
230.
PommierY, SordetO, AntonyS, HaywardRL, KohnKW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene, 23:2934–2949. 2004.
231.
PsahouliaFH, DrosopoulosKG, DoubravskaL, AnderaL, PintzasA. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther, 6:2591–2599. 2007.
232.
PyrkoP, SchonthalAH, HofmanFM, ChenTC, LeeAS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res, 67:9809–9816. 2007.
233.
QianF, WeiD, ZhangQ, YangS. Modulation of P-glycoprotein function and reversal of multidrug resistance by (−)-epigallocatechin gallate in human cancer cells. Biomed Pharmacother, 59:64–69. 2005.
234.
QianH, YangY, WangX. Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. Eur J Pharm Sci, 43:125–131. 2011.
235.
QuanF, PanC, MaQ, ZhangS, YanL. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother, 62:622–629. 2008.
RaiB, KaurJ, JacobsR, SinghJ. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci, 52:251–256. 2010.
238.
RaviR, BediA. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res, 62:4180–4185. 2002.
239.
ReddyRK, MaoC, BaumeisterP, AustinRC, KaufmanRJ, LeeAS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem, 278:20915–20924. 2003.
240.
RenD, VilleneuveNF, JiangT, WuT, LauA, ToppinHA, ZhangDD. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A, 108:1433–1438. 2011.
241.
RezkYA, BaluladSS, KellerRS, BennettJA. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol, 194:e23–e26. 2006.
242.
RicciMS, KimSH, OgiK, PlastarasJP, LingJ, WangW, JinZ, LiuYY, DickerDT, ChiaoPJ, FlahertyKT, SmithCD, El-DeiryWS. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 12:66–80. 2007.
243.
RiegerPT. Interferon-alpha: a clinical update. Cancer Pract, 3:356–365. 1995.
244.
RigolioR, MilosoM, NicoliniG, VillaD, ScuteriA, SimoneM, TrediciG. Resveratrol interference with the cell cycle protects human neuroblastoma SH-SY5Y cell from paclitaxel-induced apoptosis. Neurochem Int, 46:205–211. 2005.
245.
RussoM, NigroP, RosielloR, D'ArienzoR, RussoGL. Quercetin enhances CD95- and TRAIL-induced apoptosis in leukemia cell lines. Leukemia, 21:1130–1133. 2007.
246.
RussoM, PalumboR, MupoA, TostoM, IacominoG, ScognamiglioA, TedescoI, GalanoG, RussoGL. Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase Calpha. Oncogene, 22:3330–3342. 2003.
247.
SadavaD, WhitlockE, KaneSE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun, 360:233–237. 2007.
248.
SakonS, XueX, TakekawaM, SasazukiT, OkazakiT, KojimaY, PiaoJH, YagitaH, OkumuraK, DoiT, NakanoH. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J, 22:3898–3909. 2003.
249.
SallmanDA, ChenX, ZhongB, GilvaryDL, ZhouJ, WeiS, DjeuJY. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther, 6:2938–2947. 2007.
250.
SatoM, YaoVJ, ArapW, PasqualiniR. GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet, 69:97–114. 2010.
251.
SatohH, NishikawaK, SuzukiK, AsanoR, VirgonaN, IchikawaT, HagiwaraK, YanoT. Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res Commun Mol Pathol Pharmacol, 113–114:149–158. 2003.
252.
ScandlynMJ, StuartEC, Somers-EdgarTJ, MenziesAR, RosengrenRJ. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer, 99:1056–1063. 2008.
253.
ScarlattiF, SalaG, RicciC, MaioliC, MilaniF, MinellaM, BotturiM, GhidoniR. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett, 253:124–130. 2007.
254.
ShanafeltTD, CallTG, ZentCS, LaPlantB, BowenDA, RoosM, SecretoCR, GhoshAK, KabatBF, LeeMJ, YangCS, JelinekDF, ErlichmanC, KayNE. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol, 27:3808–3814. 2009.
255.
ShanafeltTD, LeeYK, CallTG, NowakowskiGS, DingliD, ZentCS, KayNE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res, 30:707–712. 2006.
256.
ShankarS, ChenQ, SiddiquiI, SarvaK, SrivastavaRK. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4′, 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal, 2:7. 2007.
257.
ShankarS, GanapathyS, ChenQ, SrivastavaRK. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol Cancer, 7:16. 2008.
258.
SharmaRA, EudenSA, PlattonSL, CookeDN, ShafayatA, HewittHR, MarczyloTH, MorganB, HemingwayD, PlummerSM, PirmohamedM, GescherAJ, StewardWP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res, 10:6847–6854. 2004.
259.
SharmaRA, McLellandHR, HillKA, IresonCR, EudenSA, MansonMM, PirmohamedM, MarnettLJ, GescherAJ, StewardWP. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res, 7:1894–1900. 2001.
260.
ShehzadA, WahidF, LeeYS. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim), 343:489–499. 2010.
261.
ShenJ, HughesC, ChaoC, CaiJ, BartelsC, GessnerT, SubjeckJ. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci U S A, 84:3278–3282. 1987.
262.
ShenJ, TaiYC, ZhouJ, Stephen WongCH, CheangPT, Fred WongWS, XieZ, KhanM, HanJH, ChenCS. Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling. Exp Hematol, 35:75–83. 2007.
263.
ShenM, ChanTH, DouQP. Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization. Anticancer Agents Med Chem, 12:891–901. 2012.
264.
ShenQ, TianF, JiangP, LiY, ZhangL, LuJ, LiJ. EGCG enhances TRAIL-mediated apoptosis in human melanoma A375 cell line. J Huazhong Univ Sci Technolog Med Sci, 29:771–775. 2009.
265.
ShervingtonA, PawarV, MenonS, ThakkarD, PatelR. The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol Biol Rep, 36:1181–1186. 2009.
266.
ShimizuM, DeguchiA, LimJT, MoriwakiH, KopelovichL, WeinsteinIB. (−)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res, 11:2735–2746. 2005.
267.
ShobaG, JoyD, JosephT, MajeedM, RajendranR, SrinivasPS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med, 64:353–356. 1998.
268.
SiHY, LiDP, WangTM, ZhangHL, RenFY, XuZG, ZhaoYY. Improving the anti-tumor effect of genistein with a biocompatible superparamagnetic drug delivery system. J Nanosci Nanotechnol, 10:2325–2331. 2010.
269.
SiddiquiIA, AdhamiVM, BharaliDJ, HafeezBB, AsimM, KhwajaSI, AhmadN, CuiH, MousaSA, MukhtarH. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res, 69:1712–1716. 2009.
270.
SiddiquiIA, MalikA, AdhamiVM, AsimM, HafeezBB, SarfarazS, MukhtarH. Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene, 27:2055–2063. 2008.
271.
SiegelinMD, HabelA, GaiserT. Epigalocatechin-3-gallate (EGCG) downregulates PEA15 and thereby augments TRAIL-mediated apoptosis in malignant glioma. Neurosci Lett, 448:161–165. 2008.
272.
SiegelinMD, ReussDE, HabelA, RamiA, von DeimlingA. Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol, 11:122–131. 2009.
273.
SiegelinMD, SiegelinY, HabelA, GaiserT. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis. Neurosci Lett, 453:92–97. 2009.
274.
SinghalA, JainH, SinghalV, EliasEJ, ShowkatA. Colon-targeted quercetin delivery using natural polymer to enhance its bioavailability. Pharmacognosy Res, 3:35–39. 2011.
275.
SirichanchuenB, PengsuparpT, ChanvorachoteP. Long-term cisplatin exposure impairs autophagy and causes cisplatin resistance in human lung cancer cells. Mol Cell Biochem, 364:11–18. 2012.
276.
SlamonDJ, Leyland-JonesB, ShakS, FuchsH, PatonV, BajamondeA, FlemingT, EiermannW, WolterJ, PegramM, BaselgaJ, NortonL. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344:783–792. 2001.
277.
SleijferS, BanninkM, Van GoolAR, KruitWH, StoterG. Side effects of interferon-alpha therapy. Pharm World Sci, 27:423–431. 2005.
278.
SmithAJ, KavuruP, WojtasL, ZaworotkoMJ, ShytleRD. Cocrystals of quercetin with improved solubility and oral bioavailability. Mol Pharm, 8:1867–1876. 2011.
279.
SmithCD, ZilfouJT. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem, 270:28145–28152. 1995.
280.
SomasundaramS, EdmundNA, MooreDT, SmallGW, ShiYY, OrlowskiRZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res, 62:3868–3875. 2002.
281.
SongX, LiuX, ChiW, LiuY, WeiL, WangX, YuJ. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol, 58:776–784. 2006.
282.
SongZ, FengR, SunM, GuoC, GaoY, LiL, ZhaiG. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci, 354:116–123. 2011.
283.
SouzaPS, VasconcelosFC, De Souza ReisFR, Nestal De MoraesG, MaiaRC. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol, 39:925–933. 2011.
284.
SreekanthCN, BavaSV, SreekumarE, AntoRJ. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene, 30:3139–3152. 2011.
285.
SuYJ, TsaiMS, KuoYH, ChiuYF, ChengCM, LinST, LinYW. Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells. Mol Pharmacol, 77:633–643. 2010.
286.
SubbaramaiahK, HartJC, NortonL, DannenbergAJ. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem, 275:14838–14845. 2000.
287.
SuganumaM, KurusuM, SuzukiK, TasakiE, FujikiH. Green tea polyphenol stimulates cancer preventive effects of celecoxib in human lung cancer cells by upregulation of GADD153 gene. Int J Cancer, 119:33–40. 2006.
288.
SuganumaM, OkabeS, KaiY, SueokaN, SueokaE, FujikiH. Synergistic effects of (−)-epigallocatechin gallate with (−)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res, 59:44–47. 1999.
289.
SwainSM, LippmanME, EganEF, DrakeJC, SteinbergSM, AllegraCJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol, 7:890–899. 1989.
TanL, KwokRP, ShuklaA, KshirsagarM, ZhaoL, OpipariAWJr., LiuJR. Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells. Cancer, 117:784–794. 2011.
292.
TangH, MurphyCJ, ZhangB, ShenY, Van KirkEA, MurdochWJ, RadoszM. Curcumin polymers as anticancer conjugates. Biomaterials, 31:7139–7149. 2010.
293.
TangJ, XuN, JiH, LiuH, WangZ, WuL. Eudragit nanoparticles containing genistein: formulation, development, and bioavailability assessment. Int J Nanomed, 6:2429–2435. 2011.
294.
TangX, WangH, FanL, WuX, XinA, RenH, WangXJ. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med, 50:1599–1609. 2011.
295.
TaniguchiT, TischkowitzM, AmezianeN, HodgsonSV, MathewCG, JoenjeH, MokSC, D'AndreaAD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med, 9:568–574. 2003.
296.
ThallingerC, WolschekMF, WacheckV, MaierhoferH, GunsbergP, PolterauerP, PehambergerH, MoniaBP, SelzerE, WolffK, JansenB. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol, 120:1081–1086. 2003.
297.
ThangasamyT, SittadjodyS, LimesandKH, BurdR. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol, 30:371–387. 2008.
298.
ThangasamyT, SittadjodyS, MitchellGC, MendozaEE, RadhakrishnanVM, LimesandKH, BurdR. Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer, 10:282. 2010.
299.
ToninoSH, van LaarJ, van OersMH, WangJY, ElderingE, KaterAP. ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene, 30:701–713. 2011.
300.
UgurelS, RapplG, TilgenW, ReinholdU. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res, 7:1282–1286. 2001.
301.
VaishampayanU, HussainM, BanerjeeM, SerenS, SarkarFH, FontanaJ, FormanJD, CherML, PowellI, PontesJE, KucukO. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer, 59:1–7. 2007.
302.
van UdenP, KennethNS, RochaS. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J, 412:477–484. 2008.
303.
Villalona-CaleroMA, OttersonGA, WientjesMG, WeberF, Bekaii-SaabT, YoungD, MurgoAJ, JensenR, YehTK, WeiY, ZhangY, EngC, GreverM, AuJL. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Ann Oncol, 19:1903–1909. 2008.
304.
VinallRL, HwaK, GhoshP, PanCX, LaraPNJr., de Vere WhiteRW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res, 13:6204–6216. 2007.
305.
WangJ, YinY, HuaH, LiM, LuoT, XuL, WangR, LiuD, ZhangY, JiangY. Blockade of GRP78 sensitizes breast cancer cells to microtubules-interfering agents that induce the unfolded protein response. J Cell Mol Med, 13:3888–3897. 2009.
306.
WangL, LeeIM, ZhangSM, BlumbergJB, BuringJE, SessoHD. Dietary intake of selected flavonols, flavones, and flavonoid-rich foods and risk of cancer in middle-aged and older women. Am J Clin Nutr, 89:905–912. 2009.
307.
WangP, AronsonWJ, HuangM, ZhangY, LeeRP, HeberD, HenningSM. Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila), 3:985–993. 2010.
308.
WangQ, WiederR. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene, 23:426–433. 2004.
WangW, McLeodHL, CassidyJ, Collie-DuguidES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol, 59:839–845. 2007.
311.
WangW, SunYP, HuangXZ, HeM, ChenYY, ShiGY, LiH, YiJ, WangJ. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol, 79:1134–1140. 2010.
312.
WeiD, MeiY, LiuJ. Quantification of doxorubicin and validation of reversal effect of tea polyphenols on multidrug resistance in human carcinoma cells. Biotechnol Lett, 25:291–294. 2003.
313.
WellerM, MalipieroU, AguzziA, ReedJC, FontanaA. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest, 95:2633–2643. 1995.
314.
XieX, TaoQ, ZouY, ZhangF, GuoM, WangY, WangH, ZhouQ, YuS. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J Agric Food Chem, 59:9280–9289. 2011.
315.
XingH, WengD, ChenG, TaoW, ZhuT, YangX, MengL, WangS, LuY, MaD. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett, 261:108–119. 2008.
316.
XuX, ChenK, KobayashiS, TimmD, LiangQ. Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther, 341:183–195. 2012.
317.
YamamotoT, StaplesJ, WatahaJ, LewisJ, LockwoodP, SchoenleinP, RaoS, OsakiT, DickinsonD, KamataniT, SchusterG, HsuS. Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)diammine dichloride. Anticancer Res, 24:3065–3073. 2004.
318.
YamauchiY, IzumiY, AsakuraK, HayashiY, NomoriH. Curcumin Induces Autophagy in ACC-MESO-1 Cells. Phytother Res, 2012[Epub ahead of print]DOI:10.1002/ptr.4645.
319.
YanM, MyungSJ, FinkSP, LawrenceE, LutterbaughJ, YangP, ZhouX, LiuD, RerkoRM, WillisJ, DawsonD, TaiHH, Barnholtz-SloanJS, NewmanRA, BertagnolliMM, MarkowitzSD. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A, 106:9409–9413. 2009.
320.
YangJ, LiH, ChenYY, WangXJ, ShiGY, HuQS, KangXL, LuY, TangXM, GuoQS, YiJ. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic Biol Med, 37:2027–2041. 2004.
321.
YapWN, ZaidenN, LukSY, LeeDT, LingMT, WongYC, YapYL. In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology, 85:248–258. 2010.
322.
YiJ, YangJ, HeR, GaoF, SangH, TangX, YeRD. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res, 64:108–116. 2004.
323.
YoungLC, CamplingBG, ColeSP, DeeleyRG, GerlachJH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res, 7:1798–1804. 2001.
324.
YuD, LiuB, TanM, LiJ, WangSS, HungMC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene, 13:1359–1365. 1996.
325.
ZhangB, ShiZL, LiuB, YanXB, FengJ, TaoHM. Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB. Anticancer Drugs, 21:288–296. 2010.
326.
ZhangH, LiB, BaiSW, WangHJ. Constitutively active Akt contributes to vincristine resistance in human retinoblastoma cells. Cancer Invest, 28:156–165. 2010.
327.
ZhangK, MackP, WongKP. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol, 12:871–882. 1998.
328.
ZhangL, ChangCJ, BacusSS, HungMC. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res, 55:3890–3896. 1995.
329.
ZhangL, HungMC. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene, 12:571–576. 1996.
330.
ZhangL, LauYK, XiaW, HortobagyiGN, HungMC. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res, 5:343–353. 1999.
331.
ZhangQ, WeiD, LiuJ. In vivo reversal of doxorubicin resistance by (−)-epigallocatechin gallate in a solid human carcinoma xenograft. Cancer Lett, 208:179–186. 2004.
332.
ZhangX, JinTG, YangH, DeWolfWC, Khosravi-FarR, OlumiAF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res, 64:7086–7091. 2004.
333.
ZhangXM, ChenJ, XiaYG, XuQ. Apoptosis of murine melanoma B16-BL6 cells induced by quercetin targeting mitochondria, inhibiting expression of PKC-alpha and translocating PKC-delta. Cancer Chemother Pharmacol, 55:251–262. 2005.
334.
ZhouBB, BartekJ. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer, 4:216–225. 2004.
335.
ZhouS, ZhaoL, KuangM, ZhangB, LiangZ, YiT, WeiY, ZhaoX. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?Cancer Lett, 323:115–127. 2012.
336.
ZhuA, WangX, GuoZ. Study of tea polyphenol as a reversal agent for carcinoma cell lines' multidrug resistance (study of TP as a MDR reversal agent)Nucl Med Biol, 28:735–740. 2001.